JP2010516708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516708A5 JP2010516708A5 JP2009546582A JP2009546582A JP2010516708A5 JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5 JP 2009546582 A JP2009546582 A JP 2009546582A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2010516708 A5 JP2010516708 A5 JP 2010516708A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89701207P | 2007-01-22 | 2007-01-22 | |
| PCT/US2008/051734 WO2008091911A2 (en) | 2007-01-22 | 2008-01-22 | Use of antibody conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010516708A JP2010516708A (ja) | 2010-05-20 |
| JP2010516708A5 true JP2010516708A5 (https=) | 2012-03-01 |
Family
ID=39645132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009546582A Pending JP2010516708A (ja) | 2007-01-22 | 2008-01-22 | 抗体結合体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100143358A1 (https=) |
| EP (1) | EP2109625A4 (https=) |
| JP (1) | JP2010516708A (https=) |
| AU (1) | AU2008207948A1 (https=) |
| CA (1) | CA2676234A1 (https=) |
| WO (1) | WO2008091911A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2224961A1 (en) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells |
| WO2010044894A1 (en) | 2008-10-15 | 2010-04-22 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotonic dystrophy |
| US9155801B2 (en) | 2009-05-28 | 2015-10-13 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
| AU2010260145B2 (en) | 2009-06-15 | 2015-08-20 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Myotubular Myopathy using chimeric polypeptides comprising myotubularin 1 (MTM1) polypeptides |
| JP6178785B2 (ja) * | 2011-04-01 | 2017-08-09 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用 |
| CA2832184A1 (en) * | 2011-04-07 | 2012-10-11 | Memorial Sloan Kettering Cancer Center | Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer |
| CA2907072A1 (en) | 2012-03-16 | 2013-09-19 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of dmpk |
| US12195550B2 (en) * | 2012-03-30 | 2025-01-14 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| US9283272B2 (en) * | 2012-03-30 | 2016-03-15 | The United States Of America As Represented By The Department Of Veterans Affairs | Targeting intracellular target-binding determinants with intracellular antibodies |
| WO2013177428A1 (en) * | 2012-05-23 | 2013-11-28 | Valerion Therapeutics, Inc. | Methods for increasing muscle contractility |
| AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
| AU2015204446A1 (en) | 2014-01-13 | 2016-07-14 | Valerion Therapeutics, Llc | Internalizing moieties |
| US10040867B2 (en) | 2014-03-04 | 2018-08-07 | Yale University | Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations |
| US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
| CA2995673A1 (en) | 2014-08-27 | 2016-03-03 | Valerion Therapeutics, Llc | Internalizing moieties for treatment of cancer |
| CN109069644B (zh) | 2015-10-08 | 2022-10-28 | 犹他大学研究基金会 | 用于预防或治疗癌症的方法和组合物 |
| WO2017189483A1 (en) | 2016-04-25 | 2017-11-02 | The Johns Hopkins University | Znt8 assays for drug development and pharmaceutical compositions |
| WO2017218824A1 (en) | 2016-06-15 | 2017-12-21 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
| EP3471777A1 (en) | 2016-06-15 | 2019-04-24 | Yale University | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors |
| EP3652540A4 (en) | 2017-07-12 | 2021-04-07 | The Johns Hopkins University | PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES |
| WO2019152806A1 (en) * | 2018-02-01 | 2019-08-08 | Yale University | Compositions and methods for enhancing nuclear translocation |
| US12239720B2 (en) | 2018-04-06 | 2025-03-04 | Oncolyze, Inc. | Compositions for use in lysis of selective cancer cells |
| WO2020037174A1 (en) | 2018-08-16 | 2020-02-20 | The Johns Hopkins University | Antibodies to human znt8 |
| EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
| WO2021042060A1 (en) | 2019-08-30 | 2021-03-04 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| US12366570B2 (en) | 2019-10-01 | 2025-07-22 | The Johns Hopkins University | Cell-based ZNT8 assay |
| CA3228876A1 (en) * | 2021-08-20 | 2023-02-23 | Dax Fu | Cell-surface antibody to a specific biomarker of pancreatic beta-cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812397A (en) * | 1987-02-10 | 1989-03-14 | The Regents Of The University Of California | MAB-anti-DNA related to nephritis |
| JP2000507225A (ja) * | 1996-03-08 | 2000-06-13 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム |
| AU7577600A (en) * | 1999-09-13 | 2001-04-17 | Cornell Research Foundation Inc. | Delivering to eucaryotic cells bacterial proteins that are secreted via type iiisecretion systems |
-
2008
- 2008-01-22 AU AU2008207948A patent/AU2008207948A1/en not_active Abandoned
- 2008-01-22 CA CA002676234A patent/CA2676234A1/en not_active Abandoned
- 2008-01-22 US US12/523,438 patent/US20100143358A1/en not_active Abandoned
- 2008-01-22 WO PCT/US2008/051734 patent/WO2008091911A2/en not_active Ceased
- 2008-01-22 EP EP08713907A patent/EP2109625A4/en not_active Withdrawn
- 2008-01-22 JP JP2009546582A patent/JP2010516708A/ja active Pending
-
2016
- 2016-09-15 US US15/266,919 patent/US20170096497A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516708A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| CA2747064C (en) | Monoclonal antibodies directed against lg4/5 domain of alpha3 chain of human laminin-5 | |
| RU2018114904A (ru) | Антитело против garp | |
| JP2016533721A5 (https=) | ||
| JP2021528047A5 (https=) | ||
| JP2014158469A5 (https=) | ||
| RU2009149205A (ru) | Моноклональные антитела против клаудина-18 для лечения рака | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| RU2013152164A (ru) | Анти-в7-н3-антитело | |
| RU2008125324A (ru) | Моноклональные антитела к клаудину-18 для лечения рака | |
| SI2342234T1 (en) | MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL | |
| JP2022522344A5 (https=) | ||
| JP2024531409A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| WO2012113266A1 (zh) | 识别肿瘤起始细胞的抗体和抗原及其应用 | |
| JP2023546743A5 (https=) | ||
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| JP2010509931A5 (https=) | ||
| JP2019205480A5 (https=) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2019513410A5 (https=) | ||
| TW201713700A (zh) | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 |